GlassScriptPhysician profile
Roshni Patel
NPI 1548851538
$3,986.56
in general payments reported to CMS, 2019-2025
24 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,538 · 2022: $1,539 · 2023: $525 · 2024: $148 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $842.35 | 2021-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $605.45 | 2021-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $529.41 | 2021-2022 | |
| Abbvie INC. | $451.95 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $239.98 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.29 | 2021-2023 | Trintellix |
| Axsome Therapeutics, INC. | $194.98 | 2022-2023 | Auvelity |
| Neos Therapeutics, LP | $169.39 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $119.02 | 2021-2023 | Qelbree |
| Almatica Pharma LLC | $86.76 | 2022-2023 | Loreev Xr |
| Merck Sharp & Dohme LLC | $69.63 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $65.43 | 2022-2025 | Uzedy |
| Tris Pharma INC | $64.61 | 2021-2022 | |
| Lundbeck LLC | $56.25 | 2022-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $52.03 | 2022-2023 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $46.37 | 2021 | |
| Bausch Health US, LLC | $37.85 | 2022 | |
| Corium, LLC | $32.43 | 2022 | |
| Idorsia Pharmaceuticals US INC | $32.03 | 2022 | |
| Avanir Pharmaceuticals, INC. | $20.07 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.44 | 2021 | |
| Alfasigma USA, INC. | $16.58 | 2022 | |
| Eisai INC. | $15.70 | 2021 | |
| Vivus LLC | $15.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshni Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.